Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
7.69
-0.04 (-0.52%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Bioventus Statistics

Total Valuation

Bioventus has a market cap or net worth of $508.75 million. The enterprise value is $820.57 million.

Market Cap 508.75M
Enterprise Value 820.57M

Important Dates

The next estimated earnings date is Tuesday, May 6, 2025, before market open.

Earnings Date May 6, 2025
Ex-Dividend Date n/a

Share Statistics

Bioventus has 66.16 million shares outstanding. The number of shares has increased by 3.03% in one year.

Current Share Class 66.16M
Shares Outstanding 66.16M
Shares Change (YoY) +3.03%
Shares Change (QoQ) +0.30%
Owned by Insiders (%) 2.24%
Owned by Institutions (%) 33.10%
Float 34.45M

Valuation Ratios

PE Ratio n/a
Forward PE 11.74
PS Ratio 0.86
Forward PS 0.91
PB Ratio 3.40
P/TBV Ratio n/a
P/FCF Ratio 13.39
P/OCF Ratio 13.05
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.91, with an EV/FCF ratio of 21.71.

EV / Earnings n/a
EV / Sales 1.43
EV / EBITDA 13.91
EV / EBIT 20.60
EV / FCF 21.71

Financial Position

The company has a current ratio of 1.31, with a Debt / Equity ratio of 1.92.

Current Ratio 1.31
Quick Ratio 0.80
Debt / Equity 1.92
Debt / EBITDA 5.50
Debt / FCF 9.42
Interest Coverage 1.03

Financial Efficiency

Return on equity (ROE) is -21.55% and return on invested capital (ROIC) is 4.21%.

Return on Equity (ROE) -21.55%
Return on Assets (ROA) 3.24%
Return on Invested Capital (ROIC) 4.21%
Return on Capital Employed (ROCE) 7.70%
Revenue Per Employee $616,430
Profits Per Employee -$36,067
Employee Count 930
Asset Turnover 0.75
Inventory Turnover 2.01

Taxes

Income Tax -5.29M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +85.30% in the last 52 weeks. The beta is 0.92, so Bioventus's price volatility has been similar to the market average.

Beta (5Y) 0.92
52-Week Price Change +85.30%
50-Day Moving Average 9.17
200-Day Moving Average 10.09
Relative Strength Index (RSI) 37.70
Average Volume (20 Days) 352,598

Short Selling Information

The latest short interest is 742,601, so 1.12% of the outstanding shares have been sold short.

Short Interest 742,601
Short Previous Month 811,262
Short % of Shares Out 1.12%
Short % of Float 2.16%
Short Ratio (days to cover) 1.83

Income Statement

In the last 12 months, Bioventus had revenue of $573.28 million and -$33.54 million in losses. Loss per share was -$0.52.

Revenue 573.28M
Gross Profit 388.23M
Operating Income 39.84M
Pretax Income -48.54M
Net Income -33.54M
EBITDA 58.98M
EBIT 39.84M
Loss Per Share -$0.52
Full Income Statement

Balance Sheet

The company has $41.58 million in cash and $356.06 million in debt, giving a net cash position of -$314.47 million or -$4.75 per share.

Cash & Cash Equivalents 41.58M
Total Debt 356.06M
Net Cash -314.47M
Net Cash Per Share -$4.75
Equity (Book Value) 185.60M
Book Value Per Share 2.25
Working Capital 65.21M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $38.80 million and capital expenditures -$1.01 million, giving a free cash flow of $37.79 million.

Operating Cash Flow 38.80M
Capital Expenditures -1.01M
Free Cash Flow 37.79M
FCF Per Share $0.57
Full Cash Flow Statement

Margins

Gross margin is 67.72%, with operating and profit margins of 6.95% and -5.85%.

Gross Margin 67.72%
Operating Margin 6.95%
Pretax Margin -8.57%
Profit Margin -5.85%
EBITDA Margin 10.29%
EBIT Margin 6.95%
FCF Margin 6.59%

Dividends & Yields

Bioventus does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -3.03%
Shareholder Yield -3.03%
Earnings Yield -6.63%
FCF Yield 7.47%

Analyst Forecast

The average price target for Bioventus is $15.00, which is 95.06% higher than the current price. The consensus rating is "Strong Buy".

Price Target $15.00
Price Target Difference 95.06%
Analyst Consensus Strong Buy
Analyst Count 4
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Bioventus has an Altman Z-Score of 0.95 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 0.95
Piotroski F-Score 6